CV Sciences Inc (QB) (CVSI)

The U.S. grocery market is notoriously crowded. Independent health food stores have highly limited shelf space. If a brand does not provide marketing support, in-store demos, or digital ads, the product will sit on the shelf, expire, and be discontinued by the retailer.
Likely Corporate Motivation
It is rarely for genuine commercial growth. Instead, it is often a defensive or engineered corporate maneuver designed to:
Artificially inflate assets on the balance sheet.
Diversify away from a failing core CBD business to appease lenders.
Create a justification to issue new shares (diluting investors) under the guise of "international expansion."

💥 Lots of incredible breaking CBD news:

💥 https://pubmed.ncbi.nlm.nih.gov/42142680/

💥 https://themarijuanaherald.com/2026/06/cannabis-horse-2/

💥 https://themarijuanaherald.com/2026/06/oral-cbd-may-help-lower-blood-pressure-new-review-finds/

💥 https://themarijuanaherald.com/2026/06/clinical-trial-finds-medical-cannabis-extracts-improve-cancer-related-symptoms-in-about-half-of-patients/

💥 https://themarijuanaherald.com/2026/06/cannabis-leaves-could-be-valuable-source-of-antioxidant-compounds-new-study-finds/

💥 https://themarijuanaherald.com/2026/06/hemp-seed-oil-nanoemulgel-shows-promise-for-treating-psoriasis/

💥 https://themarijuanaherald.com/2026/06/cbd-hesperetin-formulation-greatly-improves-cbd-solubility-2/

💥 https://themarijuanaherald.com/2026/06/cannabinoid-based-therapies-linked-to-reduced-agitation-in-alzheimers-patients-meta-analysis-finds/

💥 https://themarijuanaherald.com/2026/06/cannabis-horse-2/

💥 https://themarijuanaherald.com/2026/06/review-finds-just-31-of-consumer-cbd-products-meet-label-accuracy-standard/

💥 https://link.springer.com/article/10.1007/s10067-026-08166-z

💥 https://pubmed.ncbi.nlm.nih.gov/42303550/

💥 https://www.medrxiv.org/content/10.64898/2026.05.31.26354558v1

💥 https://t.co/heL6fuRvZy— Marc Landers (@marclanders) June 20, 2026

💥 https://pubmed.ncbi.nlm.nih.gov/42321899/

WQLF SAYS: More dis- information from TALISMAN 33 and a Half 🧌. The EPS has stayed steady and a recent Quarter of Increasing due to the two Acquisitions. The EPS steadiness and increase is due to the Acquisitions. They would be higher if revenue from CV SCIENCES had not decreased. The Gross Margin s have increased Since the two Acquisitions.The two Acquisitions have been Accretive YQU Now Understand YQU Understand. Have Mercy WQLF ahoooooo


Q: Would CV SCIENCES Subsidiaries considered to be non-accretive ?

Ai Generated:

An acquisition is considered accretive if the buying company's earnings per share (EPS) increase, and dilutive (or non-accretive) if they decrease after the transaction. CV Sciences (OTC: CVSI) generally structures its subsidiaries to be accretive over time, utilizing them to in-source production, realize cost savings, and enter new distribution networks.CV Sciences has established or acquired several key subsidiaries:Elevated Softgels, LLC: Acquired by CV Sciences in May 2024 for up to $1 million in a mix of cash and stock. Management expected this acquisition to be accretive in its first full year.

Elevated Softgels gave the parent company the ability to in-source production for its +PlusCBD brand and reduced minimum order quantity (MOQ) capabilities, which generated meaningful cost savings and operational efficiencies.

Cultured Foods Sp. z.o.o.: Acquired in December 2023, this European plant-based protein company serves as a strategic addition. While initially immaterial to immediate revenue, CV Sciences utilizes Cultured Foods and its U.S. brand Lunar Fox to scale within the growing plant-based protein market. Historically, CV Sciences has been operating with net and operating losses as it attempts to integrate and scale these consumer and drug development divisions. However, from an M&A perspective, its recent subsidiary acquisitions are fundamentally designed as accretive growth investments intended to improve long-term margins and EPS.



Ai Generated:

CV Sciences (OTCPK: CVSI) has consistently reported diluted EPS of $-0.01 or $-0.00 on a per-share basis from 2023 through early 2026, operating near break-even. The consumer wellness company continues to work toward sustained profitability by improving gross margins and lowering operating expenses.

A detailed breakdown of recent annual and trailing 12-month (TTM) EPS performance

:FY 2023: Reported a full-year diluted EPS of $-0.01 per share, benefiting from gross margin improvements and reduced operating expenses.

FY 2024: Full-year diluted EPS remained in line at $-0.01 per share. The company reduced operating expenses significantly but faced persistent headwinds from regulatory uncertainties in the CBD market.

FY 2025: Full-year diluted EPS was $-0.01. Product sales were $13.8 million.

TTM 2026: The trailing 12-month diluted EPS sits at $-0.01 per share, with the company aggressively managing its operating expenses.


Ai Generated:

CV Sciences (OTCQB:CVSI) has reported negative diluted Earnings Per Share (EPS) every year since 2024, primarily driven by challenging market dynamics, restrictive regulations, and fluctuating sales volumes.Annual and Trailing EPS Breakdown FY 2024: Diluted EPS of -$0.01FY 2025: Diluted EPS of -$0.01Trailing Twelve Months (TTM): EPS of -$0.01

Operational Highlights While the company has remained unprofitable, it has significantly improved its operational efficiency and reduced losses: Revenues: Sales declined from $15.7 million in 2024 to $13.8 million in 2025, largely due to temporary out-of-stock issues and restrictive CBD regulations.Operating Losses: Operating loss improved substantially from -$2.2 million in 2024 to -$0.5 million in 2025.

Adjusted EBITDA: The company has narrowed its EBITDA losses and achieved positive adjusted EBITDA during the final quarter of 2025.

Ai Generated:

CV Sciences (OTCQB: CVSI) has consistently increased its gross margins since 2023 through operational efficiencies, supply-chain improvements, and the insourcing of manufacturing. Net profit and EBITDA margins remain negative but have steadily improved toward operating cash flow break-even.

Annual Margins

Fiscal Year 2023: Gross margin was 44.3%, with a net profit margin of approximately -16%.

Fiscal Year 2024: Gross margin improved to 45.6%, and the net profit margin was approximately -6%.

Fiscal Year 2025: Gross margin continued to expand, reaching 49.0% for the year, primarily due to cost-efficient execution and acquisitions like Elevated Softgels.

2025–2026 Quarterly Gross Margins CV Sciences has seen strong, steady gross margin improvement over recent quarters, reaching its highest mark since 2019:Q2 2025: 50.9%Q3 2025: 48.5%Q4 2025: 50.5%Q1 2026: 48.9% (on revenues of $3.2 million)

Profitability & EBITDA While gross margins are healthy, the company still operates at a net loss (e.g., $(0.96) million in FY25). However, Adjusted EBITDA margins are approaching break-even. For example, the company achieved a positive Adjusted EBITDA of $0.1 million in Q4 2025 and is executing debt restructurings to fuel future growth

Yes, diluting shareholders is like taking one step back to take two steps forward when it results in growth. But if the real purpose is to fund overhead, it becomes very bad for shareholders. For example, acquiring non-accretive “going concerns”.

WQLF SAYS:

Q: If CV SCIENCES had not increased their Authorized Shares and could not pay back their loans to Streeterville Capital and not be able to utilize a debt for equity swap, would they have become insolvent?

Ai Generated:

Yes, if CV Sciences (CVSI) had exhausted its authorized shares and was blocked from executing debt-for-equity swaps, it would have faced a severely elevated risk of technical or legal insolvency.

Here is why this scenario would have threatened the company's survival:

1. Inability to Meet Cash Obligations

Insolvency generally takes two forms: balance sheet insolvency (liabilities exceed assets) and equitable/cash-flow insolvency (inability to pay debts as they come due). Without the ability to repay Streeterville Capital with equity, CV Sciences would be forced to pay off its significant Streeterville notes in cash. Given the company's tight liquidity—its SEC filings reflect a minimal cash balance (e.g., $309,000 in cash against millions in current liabilities)—it would have been unable to service these obligations with its operational cash flow.

2. The Danger of Defaults and Cross-Defaults

If a company fails to repay a loan or note upon maturity, it enters a payment default. Not only would this allow Streeterville to aggressively call the loan or seize collateral, but it would often trigger cross-defaults across the company's other financial obligations, vendor accounts, and leases. Once in default, creditors can force companies into bankruptcy.

3. Blocked Capital-Raising Avenues

A company in a distressed debt scenario usually turns to secondary offerings (selling common stock) to raise cash and pay off creditors. However, if the company cannot issue new shares (because it hit its authorized share limit and shareholders refused to increase it), this crucial lifeline is cut off.

4. Limited Alternatives

Without a debt-to-equity swap or the ability to issue shares to raise emergency cash, management would have been left with highly drastic, difficult measures. They likely would have been forced to pursue extreme cost-cutting, liquidate core business assets (like their nutraceuticals or plant-based food lines), or seek protection under bankruptcy laws in order to restructure or sell the company entirely.

Interesting discussion.
The part I agree with is that increasing authorized shares gave CV Sciences more flexibility. That’s simply how corporate finance works. Additional authorized shares can be used for financing, acquisitions, debt restructuring, employee compensation, and other strategic purposes.
Where I disagree is the leap from “more flexibility” to “the company would have been crippled or insolvent without it.”
Those are two very different statements.
A lack of authorized shares does not automatically cause bankruptcy. Insolvency is a cash flow and balance sheet problem, not an authorized share count problem.
Could it have limited financing options? Absolutely.
Could it have made stock-based acquisitions more difficult? Absolutely.
Could it have reduced management’s flexibility? Absolutely.
But claiming that failure to increase authorized shares would have directly threatened the company’s survival requires evidence, not assumptions.
As investors, we should distinguish between:

• Facts

• Management goals

• Possibilities

• Certainties
The strongest argument is that the additional shares expanded strategic options.
The weakest argument is that the company could not have survived without them.
Read the filings. Follow the evidence. Let the facts do the talking.

WQLF SAYS: Read and Reap. Increasing the Authorized Shares was the WISEST DECISION by CV SCIENCES Management what so ever. YQU NOW Understand YQU Understand. Have Mercy WQLF ahoooooo

. Uninformed TALISMAN 33 and a Half Said:

Remember this comment? Were they referring to increasing authorized shares? It was voted down by shareholders… that is until the preferred vote was created to revers it.


Q: If CV SCIENCES hadn't increased their Authorized Shares, would they have become insolvent, and would they be in a position to Acquire other companies?

Ai Generated:

If CV Sciences had not increased their authorized shares, they would have faced severe operational bottlenecks, but it would not have directly caused bankruptcy or insolvency. Increasing the authorized share count gave them the vital ability to issue new equity, which they needed to successfully restructure debt and execute stock-based acquisitions.

The Real Impact of Authorized Shares on the Company

Insolvency Risks vs. Equity Reliance:

Insolvency occurs when a company's cash flow is insufficient to pay its debts or when its liabilities exceed its assets. While CV Sciences operates with a large accumulated deficit (over $88 million) and has faced periods of negative operating cash flows, their core survival depends on debt restructuring, cost-cutting, and operational profitability, rather than just share authorizations. Not increasing the authorized share count wouldn't automatically trigger insolvency, but it would have starved the company of the flexibility needed to pay down debt through equity conversions.

Capacity to Acquire Other Companies:

Without expanding authorized shares, CV Sciences' ability to acquire other companies (like Cultured Foods, Elevated Softgels, and their pursuit of Extract Labs) would have been severely limited. They would have been restricted to cash-only acquisitions, which is not feasible given their tight cash balances (hovering around $0.3 million). The ability to issue restricted common stock has been the primary vehicle used to fund these strategic buyouts without draining their working capital.

Current State of Expansion:

Despite prior expansions, shareholders recently rejected an attempt by the board to authorize a massive reverse split and restructure authorized capital at the June 2026 Annual Meeting. Nevertheless, management continues to seek accretive M&A targets in the highly fragmented hemp market to utilize their operational platform

Remember this comment? Were they referring to increasing authorized shares? It was voted down by shareholders… that is until the preferred vote was created to revers it.

“And last, our public Company status provides investors with liquidity issues options that do not exist for private companies.…”

According to info shared here, Streeterville and Smithfield are now large investors. Anyone think they’re waiting for the CEO/CFO employment agreements to burn out before they become active investors and take control? I think that would be really good for shareholders because they may see value in a sales and marketing approach.

WQLF SAYS: No need to ask YQU. YQU have never been a CEO or a CFO of a Publicly held Corporation for that matter. We already Know YQU wouldn't know. We already know the answer YQU Now Understand YQU Understand. Read and Reap Have Mercy WQLF ahoooooo


Uninformed Asked:
It would be good for shareholders to see them invest their own money ( No it Isn't Good ) and increase their 15,000 share positions. Free awarded shares don’t count, ( Yes they certainly do) especially if they weren’t held to a KPI measure. If you ask me ( No need to ) they look like “rubber stamp awards”.

Q: Why doesn't the CEO and CFO of CV SCIENCES purchase stock in their company?

Ai Generated:

The CEO (Joseph Dowling) and CFO (Joerg Grasser) of CV Sciences (CVSI) have substantial, existing equity in their company. Their lack of recent open-market purchases is common for public executives. Instead, their ownership generally increases through periodic stock awards, restricted stock units (RSUs), and compensation incentives issued by the Board.

Executives rarely make large open-market stock purchases due to:

Conflict of Interest & Insider Trading Risks: Executives hold material, non-public information. Purchasing stock on the open market subjects them to intense scrutiny and complex, pre-scheduled trading requirements.

Diversification Strategies: Because their career, future earnings, and wealth are already heavily tied to the company's success, executives typically look to diversify their personal portfolios rather than funneling more cash into a single asset.

It would be good for shareholders to see them invest their own money and increase their 15,000 share positions. Free awarded shares don’t count, especially if they weren’t held to a KPI measure. If you ask me they look like “rubber stamp awards”.

Up $0.002 on $18K volume yesterday. What’s this board’s bullish take on that? MM manipulation because they want to get in on this hidden gem? Seems that the CEO/CFO ok with their $300 personally invested positions, right?

More Great Breaking CBD News:

💥 https://www.sciencedirect.com/science/article/pii/S2707368826000361

💥 https://pubmed.ncbi.nlm.nih.gov/41421545/

💥 https://pubmed.ncbi.nlm.nih.gov/42298090/

💥 https://themarijuanaherald.com/2026/06/medical-cannabis-linked-to-improvements-in-pain-sleep-and-nighttime-urination-in-parkinsons-patients/

💥 https://themarijuanaherald.com/2026/06/cbd-may-help-address-digital-era-fatigue-review-finds/

WQLF SAYS: CVSI is a BUY YQU Understand. Take advantage of the Market Manipulaters actions . Have Mercy WQLF ahoooooo

https://www.otcmarkets.com/stock/CVSI/security

WQLF SAYS: More Disinformation from TALISMAN 33 and a Half 🧌 YQU Now Understand YQU Understand. Have Mercy WQLF ahoooooo


TALISMAN 33 and a Half 🧌 SAID:

According to wolf man, they determined that NOT marketing or promoting Lunar is a smart move
Q: Why doesn't Lunar Fox Foods sell on Amazon?

Ai Generated:

Lunar Fox Food Co. does not primarily sell on Amazon because its parent company, CV Sciences, intentionally focuses on a brick-and-mortar and direct-to-consumer strategy.

Relying on Amazon is viewed by the company as a "lazy" and expensive approach for scaling, and they prefer to leverage their existing retail distribution networks.

While there is some limited or third-party international availability on Amazon (such as their Baked! egg replacement on Amazon Germany), their main U.S. approach is to stock the shelves of specialty grocers. You can find their plant-based meats, cheeses, and egg substitutes at physical health markets or directly through the Lunar Fox Food Co. website.

Would you like help finding the nearest physical retailer that carries Lunar Fox products in your area, or are you interested in seeing a list of specific items from their plant-based line?

According to wolf man, they determined that NOT marketing or promoting Lunar is a smart move. If that's part of their wider approach, it could explain today's drop despite the seven BOOM breaking news links posted below before the market opened.

looks like we are finaly toast at leaft Andrew Left when down!!!!

My, my. Down to a penny. Gee, that's too bad.

💥 Today’s Breaking News:

💥 https://www.marijuanamoment.net/our-new-study-shows-that-the-science-of-cannabis-and-sleep-extends-beyond-thc-op-ed/

💥 https://www.marijuanamoment.net/federal-science-agency-adds-new-cannabis-compounds-to-its-library-of-chemical-fingerprints/

💥🍿 https://www.wholefoodsmagazine.com/articles/18022-the-future-of-animal-health-supplements-nascs-vision-for-quality-innovation-and-regulatory-clarity

💥 https://www.nasc.cc/primary-suppliers/cv-sciences/

💥 https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(26)00234-8/fulltext

💥 https://www.jpain.org/article/S1526-5900(26)00156-2/abstract

💥 https://themarijuanaherald.com/2026/06/cbd-reduces-lung-injury-by-targeting-inflammation-oxidative-stress-and-cell-death-pathways-study/

WQLF SAYS: Have Mercy WQLF ahoooooo

Q: Why hasn't CV SCIENCES been accepted in the CMS Medicare Pilot Program?

Ai Generated:

CV Sciences has not been "accepted" into the CMS Medicare Pilot Program because the pilot is a provider-led incentive, not a program that accepts or partners directly with supplement brands.The program—officially the Substance Access Beneficiary Engagement Incentive (BEI)—is structured so that only participating healthcare providers in certain models (such as ACO REACH and the Enhancing Oncology Model) can furnish hemp products.

The primary reasons CV Sciences and other CBD companies are not direct participants include:CMS Provider Channeling: CMS does not approve specific brands or vendors. Instead, approved Accountable Care Organizations (ACOs) must independently source and secure eligible hemp products based on their own clinical judgment and sourcing safeguards.No Direct Medicare Reimbursements: Medicare does not pay for or reimburse companies or providers for the CBD products themselves. The incentive allows providers to offer up to $500 worth of eligible products annually at no cost to the beneficiary as part of their broader, value-based care arrangements.Strict Product Limitations: The CMS program only allows federally legal hemp-derived products containing no more than 0.3% delta-9 THC. It expressly excludes inhalable products, and oral products containing more than 3 mg per serving. Brands must consistently prove they meet these thresholds and maintain strict third-party testing.CV Sciences has aligned its product lines (such as +PlusCBD™) to be positioned for this market, focusing on compliance with federal thresholds and maintaining human clinical research. Ultimately, to get their products into the Medicare pathway, CV Sciences must pitch and secure agreements directly with the individual hospital networks, clinics, or ACOs participating in the model, rather than CMS directly.

FACT CHECK:


The key distinction is between “eligible” and “selected.”


To date, CMS has not publicly released a list of approved CBD brands for the Substance Access Beneficiary Engagement Incentive (BEI) program.


That means:


• There is no public CMS announcement stating that Charlotte’s Web has been officially approved by CMS.

• There is no public CMS announcement stating that CV Sciences has been officially approved by CMS.

• There is no public CMS announcement stating that Charlotte’s Web is the exclusive CBD supplier for the program.


What CMS has done is establish product eligibility standards.


If a product meets the program requirements, participating providers may have the ability to furnish those products under the BEI framework.


CV Sciences has publicly stated that it is “positioned to participate” in the program.


Charlotte’s Web has publicly discussed alignment with the program.


Neither statement is the same thing as CMS publicly announcing that the company has been selected.


Therefore, it is accurate to say:


“CV Sciences still has the opportunity to participate in the CMS BEI program.”


It is also accurate to say:


“There has been no public CMS announcement confirming that Charlotte’s Web or CV Sciences has been officially selected by CMS.”


As investors, it is important to separate facts, company statements, and assumptions.


Read. Verify. Follow the evidence.

WQLF SAYS: .Charlottes Web products Have Not been PUBLICLY STATED as being OFFICIALLY APPROVED. In the case of CV SCIENCES, the CMS Pilot Program still has time to Announce CV SCIENCES or are they already enrolled? Cornbread was never announced, so one can not reliably state that it is A True FACT YQU Now Understand YQU Understand. CV SCIENCES still has an opportunity to be selected for the CMS Medicare Pilot Program. Have Mercy WQLF ahoooooo

Q: Does CV SCIENCES still have an opportunity to benefit if the Program is Accepted?

Ai Generated:

Why They Still Have an Opportunity (If the Program is Accepted)Physician Recommendation Pathway: The CMS pilot does not alter existing federal and state laws regarding cannabis. In states where CBD is legal, seniors can still purchase CV Sciences products with their own money if their doctor recommends it.Broader Credibility: Even as a commercial retail brand, CV Sciences benefits from the mainstream spotlight. The government-led validation of CBD for senior symptom control normalizes the product and can stimulate retail sales.Future Expansion: If the pilot succeeds in generating strong outcomes data, it could pave the way for permanent, formalized Medicare/Medicaid coverage, opening up a massive federal market for commercial brands.

TANK Said: CV SCIENCES ......Officially approved by CMS” has not been demonstrated.
. And neither has Charlottes Web CBD Products as a FACT.


Q: Is it true CMS has not publicly stated that Charlottes Web products are officially approved or selected for the program.?

Ai Generated:

Yes, that is true. The Centers for Medicare and Medicaid Services (CMS) does not formally endorse, select, or approve specific brands, including Charlotte's Web products.The Facts Behind CMS and Hemp Products. CMS Policy: Under the Substance Access Beneficiary Engagement Incentive (BEI) program, participating healthcare providers and Accountable Care Organizations (ACOs) can discuss and furnish certain non-intoxicating, hemp-derived cannabinoid products (such as CBD) to eligible Medicare beneficiaries.

Eligibility vs. Approval: CMS does not evaluate, select, or endorse any specific brand. Instead, CMS sets the guidelines (e.g., federally legal hemp, <3 mg of THC per serving, and no inhalable products or synthetic cannabinoids). Products that meet these criteria are considered "eligible" for use within the pilot program.Official Disclaimer: CMS has explicitly stated in its CMS Press Release that it "does not make claims regarding the therapeutic value of these products".No FDA Approval: Because these hemp products are classified as supplements, they have not undergone traditional FDA review or approval for medical efficacy or safety.Charlotte's Web Status Like other manufacturers in the market, Charlotte's Web formulates its products to align with the regulatory thresholds set by CMS so that their items can be utilized by participating ACOs. While the company highlights its alignment with these federal frameworks in its Charlotte's Web CMMI Page, the product selection is ultimately made by the healthcare providers and patients within the program, not by CMS itself.Could you use more context on how these hemp products are integrated into Medicare pathways, or are you looking for details on the current federal litigation (such as SAM v. Kennedy) challenging this program? Let me know how to best assist!


Q: Did the CMS Medicare Pilot Program announce that Other companies besides Charlottes Web will be a part of the program?

Ai Generated:

Yes, multiple companies besides Charlotte's Web are participating in the CMS Substance Access Beneficiary Engagement Incentive (BEI) pilot program. The Centers for Medicare & Medicaid Services (CMS) allows eligible healthcare providers to offer products from various verified hemp and cannabinoid brands. Alongside Charlotte’s Web, approved suppliers within the program include:

Cornbread Hemp: Secured a contract as a supplier for the program through Alliant Purchasing.

NuLeaf Naturals: A subsidiary of High Tide that is also pursuing participation in the program.

Mary’s Medicinals: Another brand operating within the initial rollout. If you or a loved one are enrolled in a qualifying Medicare pilot like ACO REACH or the Enhancing Oncology Model (EOM), you can work directly with participating providers to choose products that meet the program's strict guidelines. Would you like to know more about the eligibility requirements for the products (such as the THC limits and non-inhalable rules) or how to verify if your specific health care provider is enrolled in the pilot?



Q: Has CV SCIENCES been selected in the CMS Medicare Pilot Program?

Ai Generated:

No, CV Sciences has not been exclusively or officially "selected" as a single vendor or designated pilot participant by the Centers for Medicare & Medicaid Services (CMS).However, they are actively positioning themselves to participate in the initiative.Here is what you should know about the initiative:The Program: CMS launched a Substance Access Beneficiary Engagement Incentive (BEI) that allows specific health care providers (specifically Accountable Care Organizations, or ACOs) participating in models like the ACO REACH Model to consult with patients on the use of hemp-derived products.Reimbursement: Under this pilot, eligible providers can recommend and provide these supplements to qualifying Medicare beneficiaries up to $500 a year, per beneficiary, in states where hemp products are legal.CV Sciences' Role: Rather than CMS selecting individual product brands, physicians are given the latitude to recommend suitable hemp products that meet regulatory standards. CV Sciences has officially announced that they are "positioned to participate" in the pilot and are marketing their +PlusCBD line to these participating health care organizations.If you are a Medicare beneficiary interested in the program, the best next step is to discuss your eligibility with a primary care provider who participates in an ACO REACH model, or check if your local health system has opted into the Substance Access BEI to see if you qualify to receive hemp-based product benefits.




Q:Has Cornbread CBD been selected in the CMS Medicare Pilot Program?

Ai Generated:

Yes, Cornbread Hemp (makers of Cornbread CBD) has been selected as an exclusive supplier for the CMS Medicare pilot program.Here are the details of their involvement:Program Specifics: The Centers for Medicare & Medicaid Services (CMS) launched the Substance Access Beneficiary Engagement Incentive (BEI) pilot program.The Partnership: Cornbread Hemp secured an exclusive contract with Alliant Purchasing, a Group Purchasing Organization (GPO) supplying roughly 68,000 healthcare provider locations nationwide.How it Works: Participating Accountable Care Organizations (ACOs) can supply eligible patients with up to $500 per year in qualifying, federally legal hemp-derived CBD products. This cost is covered by the participating provider group rather than Medicare directly.Product Limitations: Products distributed must contain no more than 0.3% delta-9 THC and exclude inhalable formats.If you are a Medicare patient interested in this program, the best next step is to consult with your primary care provider or oncologist to see if they are actively participating in the ACO REACH or Enhancing Oncology Models (EOM). You can also verify eligible models on the CMS Substance Access BEI page.





Q: Who is paying for the CBD products provided for the CMS Medicare Pilot Program?

Ai Generated:

Healthcare provider organizations participating in the CMS Innovation Center models pay for the CBD and hemp products distributed in this pilot program.Key financial and operational details of the Substance Access Beneficiary Engagement Incentive (BEI) include:No Medicare Coverage: The Centers for Medicare & Medicaid Services (CMS) does not pay for, or reimburse providers for, the hemp-derived CBD products. Beneficiaries cannot submit claims to Medicare for the products.Provider Expense: Qualifying Accountable Care Organizations (ACOs) and healthcare groups participating in the ACO REACH, Enhancing Oncology Model (EOM), and LEAD models bear the full cost of procuring and distributing the goods.Spending Limits: Participating providers can elect to furnish these eligible hemp products up to a value of $500 per year, per eligible beneficiary.For more details on the program's guidelines, you can review the official CMS Substance Access Beneficiary Engagement Incentive page.If you are interested, I can provide information on:Specific eligibility criteria for patients to qualify for the pilot.Which organizations are currently participating in this program.

FACT CHECK:


The evidence currently supports that CV Sciences’ PlusCBD oral products may be eligible for use under the CMS Substance Access Beneficiary Engagement Incentive (BEI) program if they meet the program’s THC and product requirements.


However, there is an important distinction:


CMS has not publicly stated that CV Sciences products are officially approved or selected for the program.


What we know:


• CMS allows qualifying hemp-derived oral products under the BEI model.

• Products must meet strict THC and compliance requirements.

• Products must be furnished through participating healthcare providers and approved CMS models.

• Medicare beneficiaries cannot simply purchase products at retail and seek reimbursement.


What this means:


CV Sciences appears well-positioned because of its compliance standards, testing protocols, and broad line of oral CBD products. But participation ultimately depends on adoption by participating providers and organizations within the CMS program.


In other words:


“Potentially eligible” is a fact.


“Officially approved by CMS” has not been demonstrated.


As always, read, verify, and follow the evidence.

💥🍿 https://www.marijuanamoment.net/trumps-marijuana-rescheduling-move-opens-the-door-to-interstate-cannabis-commerce-top-reform-group-says/

💥🍿 https://www.marijuanamoment.net/federal-science-agency-adds-new-cannabis-compounds-to-its-library-of-chemical-fingerprints/

💥 https://t.co/VlszILD90g— Marc Landers (@marclanders) June 15, 2026

💥 https://themarijuanaherald.com/2026/06/study-cannabichromevarin-shows-promise-as-potential-antiviral-candidate-against-measles/

💥 https://themarijuanaherald.com/2026/06/study-finds-cannabinoid-based-treatments-improved-liver-and-metabolic-markers-in-animal-model/

💥 https://themarijuanaherald.com/2026/06/study-finds-inhaled-cbd-reversed-seizure-and-inflammation-related-effects-of-chronic-nicotine-exposure/

💥 https://pubs.acs.org/doi/10.1021/acsnano.5c10942

💥 https://www.neurology.org/doi/10.1212/WNL.0000000000213060

💥 https://www.medrxiv.org/content/10.64898/2026.05.31.26354558v1

💥 https://link.springer.com/article/10.1007/s10067-026-08166-z

WQLF SAYS ABSOLUTELY YES. YQUR MOVE. Give Free Samples. Unlikely, Health Inspectors, FDA etc. wouldn't Go For That WE Understand YQU NOW Understand YQU Understand, Have Mercy WQLF ahoooooo

Talisman33
Sunday, June 14, 2026 5:02:44 PM
Post#
85061
of 85062
Do representatives from the company go out to the retail outlets and demo free samples like ambitious startups have

Q: Does CV SCIENCES have representatives that service retail store customers?

Ai Generated:

Yes, CV Sciences has dedicated representatives and strategic partners in the natural product channel that service retail store customers by stocking products, creating displays, and providing educational guidance. For specific retail support, store locations, and product availability:Retail Locations: You can locate specific stores carrying CV Sciences' products by using the PlusCBD Store Locator (note: availability varies by location and state regulations).Direct Assistance: To contact their sales, wholesale, or customer support team directly, you can reach out via the CV Sciences Contact Us page or call them toll-free at 1-855-PLUS-CBD (1-855-758-7223).

.Would you like to find specific retailers carrying CV Sciences' products in your immediate area? If you provide your city and state, I can help locate the nearest available stockists.

Wolfman Jack Said: I've Seen All Good People Turn Their Heads Each Day So Satisfied I'm On My Way You Now Understand. YQU UNDERSTAND Have Mercy ahooooo

https://share.google/jpN1ysehJ4OtTdG8u

Do representatives from the company go out to the retail outlets and demo free samples like ambitious startups have traditionally done?

WQLF SAYS: CVSI PlusCbd PlusHLTH PlusLunar Fox 🦊 Marketing YQU Understand. Have Mercy WQLF ahoooooo

Wolfman Jack Said: Boogie to LAZY 🦥 Blues You understand. Have Mercy ahoooooo

https://share.google/eAPEAEwT55pBZI6c7

WQLF SAYS: All CBD companies discount their products on their website and since CV SCIENCES does a GR8 job of marketing, they send better discounts for their repeat customers by email. Read and Reap YQU Now Understand YQU Understand. Have Mercy WQLF ahoooooo


Q: Does CV SCIENCES discounts on their website discourage their brick and mortar stores to Sell their products?

Ai Generated:

While website discounts can cause some tension between physical retailers and manufacturers, CV Sciences mitigates this channel conflict by keeping online sales focused on brand discovery and offering MAP (Minimum Advertised Price) guidelines, ensuring physical stores—like The Vitamin Shoppe or local natural grocers—remain viable.Brands like CV Sciences (makers of +PlusCBD) manage this dynamic through a few specific strategies:MAP Policies: They set strict Minimum Advertised Price guidelines, which prevent the website from heavily undercutting brick-and-mortar retailers on the shelf.

Shipping/Handling Friction: Website orders require shipping costs and wait times, whereas brick-and-mortar stores offer immediate convenience, allowing physical locations to capture impulse or immediate-need buyers.

Subscription & Loyalty Exclusives: Website discounts often require recurring subscriptions or email list promotions, which function as customer acquisition tools for the brand itself rather than direct competition with local stockists.

Wholesale Value: Brick-and-mortar stores purchase at wholesale rates, retaining a profit margin that justifies giving up shelf space, while the website sales capture a direct-to-consumer margin.

FACT CHECK SUMMARY


CV Sciences has a proven track record of building retail distribution through PlusCBD and developing relationships with distributors, retailers, and natural product buyers.


That experience may provide Lunar Fox Foods with an advantage compared to a startup entering the market with no existing retail network.


What is fact:

• CV Sciences has significant retail distribution experience.

• Lunar Fox is pursuing retail and wholesale distribution.

• Retail placement is an important channel for packaged food products.


What is opinion:

• Retail is the “best” or “only” strategy.

• Amazon is a “lazy” approach.

• Previous PlusCBD relationships guarantee Lunar Fox shelf placement or sales success.


Bottom line:


CV Sciences has already done the hard work of building industry relationships. Whether Lunar Fox becomes a major success will depend on product quality, consumer demand, retailer adoption, pricing, and execution—not simply past success with PlusCBD.

Yeah, they did a pretty strong job building the brand and securing placement in health food stores early on, particularly during Tomc’s tenure. Now they heavily discount on their own website seeming every other week. Doesn’t that undermine brick and mortar sales and discourage them from continuing to stock their products?

WQLF SAYS: Management of CV SCIENCES has been so good at Marketing and Sales of PlusCbd, PlusHLTH in Retail outlets, they have used the same plan and for Lunar Fox, WE are looking forward to their Next Acquisition
. While other companies are just ringing up Expenses in their hopes of one day selling in major retail outlets, their
only attempt is taking the lazy man's approach of selling on the Amazon Store, Lunar Fox Foods current approach of placement in Brick and Mortar 🧱 is the most effective and least expensive approach of selling Lunar Fox. The contacts that CV SCIENCES has made in the past when they peaked at 8400 Retail outlets including MAJOR Grocery stores in its placement and selling of PlusCbd, products has already formed the groundwork in their attempts to successfully place Lunar Fox in the same retail outlets. Enjoy the Free Education and ONE should Learn to utilize Ai properly. Read and Reap.YQU Now Understand YQU Understand. Have Mercy WQLF ahoooooo

Dr Joong J Fang SAID: Since one is ALWAYS posting the same negative posts over and over again, then one will see this post over and over again.



Lunar Fox Food Co.," their parent company CV Sciences primarily utilizes retail distribution and B2B marketing for their plant-based products, rather than direct-to-consumer social media selling).

Q: which is the most effective approach for Lunar Fox Foods in selling their products

Ai Generated:

For a packaged food brand like Lunar Fox Food Co., an omnichannel B2B and retail-focused approach is the most effective. By leaning into retail distribution, they bypass the high customer acquisition costs of direct-to-consumer (D2C) social media selling and place their products exactly where consumers are already shopping for groceries


Why Retail Distribution & B2B Make the Most Sense

High Impulse Purchases: Plant-based meat alternatives and egg replacements rely heavily on impulse buying. Getting products onto grocery store shelves puts them in front of consumers exactly when they are planning meals.

Capital Efficiency: Direct-to-consumer (D2C) selling requires massive marketing budgets and complex cold-chain shipping logistics. Partnering with established distributors (like Palko Services) allows the brand to move volume without building a logistical network from scratch.

Data-Backed Credibility: Their parent company, CV Sciences, is highly experienced in the natural wellness sector. Their expertise in B2B marketing and getting items on natural product shelves provides a plug-and-play advantage for Lunar Fox.


How to Build a Winning Strategy

To scale efficiently without losing their audience, the brand can successfully balance these channels:

Prioritize Natural Food Retailers: Target regional co-ops and natural grocers (such as GreensNutrition) where shoppers actively look for gluten-free, sustainable, and vegan alternatives.


Utilize Strategic B2B Marketing: Focus on building trust with retail buyers, dietitians, and food service providers to get their plant-based "Bolognese" and "Whisked" eggless mixes on menus and shelves.

Use the Website for Education, Not Just Sales: Instead of trying to drive all traffic to their Lunar Fox Foods Website, the site can act as an educational hub with recipes, ingredient transparency, and a robust "Store Locator" map to drive foot traffic to brick-and-mortar retailers.

If Lunar and/or Elevated fail, do you think the person behind it will step up and hold themselves accountable?

WQLF SAYS: If a company is selling for 40 percent, that company is taking a slice of their profits. CV SCIENCES is still getting their cut no matter what YQU Now Understand YQU Understand. Have Mercy WQLF ahoooooo


15 percent off any of their Products at Green Nutrition.

https://greensnutrition.com/collections/vendors?q=Lunar+Fox+Food&srsltid=AfmBOopeSv9nx4jeuID4BHLVchhedc5qm7mXUWupSeI1sjN1btuKxp7s


Q: Which Lunar Fox vegan products are similar and sold on Amazon?

Lunar Fox Food Co. is a 100% natural, gluten-free, plant-based food line. While many of their specialty products (like CHEDDRLY MAC! and WHISKED!) are currently available primarily at select retailers or their direct website, you can find highly comparable vegan alternatives to their entire lineup on Amazon.Here are some of the closest matches to Lunar Fox’s vegan product lineup that you can order on Amazon:

Plant-Based Meatless Crumbles (Comparable to Lunar Fox’s Mangia! and Fiesta!): Lunar Fox offers seasoned plant crumbles. For similar high-protein, ready-to-use options, try Creative Pea Beef-Style Mix or Plant Basics Hearty Plant Protein Unflavored Strips.

Vegan Cheese & Macaroni (Comparable to Cheddly! & Cheddly Mac!): Amazon carries a variety of dairy-free cheese sauces and meal kits like Plant-Based Vegan Macaroni Brands that deliver the same creamy texture.

Vegan Egg Replacers (Comparable to Whisked! & Baked!): Lunar Fox makes dedicated egg substitutes for quiches, omelets, and baking. For great baking and cooking alternatives, look into RUF Organic Vegan Egg Replacement or similar powders like Bob's Red Mill on Amazon.

Roasted Fox Nuts (Makhana): If you are looking for healthy, popped water lily (fox) seed snacks—which are named after the seed itself—Amazon features a wide variety of vegan, high-protein brands, such as Fit Fox Ranch Makhana and EatThis Superfood Roasted Foxnuts.




Are vegan products sold on Amazon similar to Lunar Fox priced similar to Lunar Fox?

Yes, vegan pantry staples similar to Lunar Fox products are sold on Amazon, and they are generally priced similarly.Lunar Fox’s plant-based, gluten-free line includes items like egg substitutes, pasta sauces, and meatless crumbles. You can find similar vegan alternatives across Amazon within these standard price ranges:Vegan Egg Substitutes: Lunar Fox’s baking and omelet mixes generally retail between $5.00 and $6.50.

On Amazon, alternative vegan egg replacements from brands like Bob’s Red Mill or Orgran typically fall in the $6.00 to $9.00 range.

Meatless Crumbles & Sauces: Lunar Fox’s seasoned crumbles and Bolognese sauces cost between $4.00 and $7.00 per package. Similarly, vegan shelf-stable crumbles and pasta alternatives on Amazon from brands like Loma Linda or Atlantic Natural Foods generally range from $3.50 to $8.00 per item.

Their current retailer is selling it for 40% off on average. How is that any different from a company like Amazon taking their cut? Unless someone specifically searches for Lunar Fox, how do they know the product even exists?

AI - Social media advertising is crucial for new Consumer Packaged Goods (CPG) products. It bypasses traditional gatekeepers, allowing brands to instantly build visual recognition, drive impulse purchases, and capture highly specific target audiences on platforms like TikTok and Instagram. Amazon is a critical proving ground for new Consumer Packaged Goods (CPG). It provides an accelerated path to market, acting as a massive digital shelf that establishes retail validation and customer reviews before approaching major brick-and-mortar stores

WQLF SAYS: Why Ask Amazon when One Can ask LUNAR FOX 🦊 NEWS YQU Now Understand YQU Understand. Have Mercy WQLF ahoooooo

. TALISMAN 33 🧌 SAID:

Ask Amazon? More like ask why they don't sell Lunar on Amazon

Dr. Joong J Fang SAID: And Now You Know WHY....

"Every time you buy something online, you pay a toll. You just never see it. It doesn't show up on your receipt. No politician voted for it. But it's baked into the price of nearly everything you buy, and it flows straight into the pockets of the most powerful corporations on earth."

"That's the racket Amazon built."

"When Amazon first opened its marketplace, it took roughly 19 cents of every dollar an independent seller earned. Today it takes close to half. Listing fees. Advertising fees. Fulfillment fees. Penalties for sellers who dare to offer a better price somewhere else. A small business owner in Ohio or Arizona forks over 45 to 50 cents on the dollar just for the privilege of reaching customers Amazon already cornered."

https://www.foxnews.com/opinion/mike-davis-congress-must-finally-kill-hidden-tax-your-online-shopping-cart

WQLF SAYS: Brick and Mortar 🧱 is the next goal YQU Now Understand YQU Understand. An investor or new investor is not concerned with the sales of Lunar 🦊 Fox. It is still in its infancy stage. If one was privvy with Marketing or Business education One would not ask such SILLY Questions. It only shows their LACK of Knowledge WE Do Understand YQU Understand. In your past and recent posts YQU refer to the past. Time to Wake Up Have Mercy WQLF ahoooooo

Naysayer Troll 🧌 Said: Nothing New

Dr. Joong J Fang Said: Investors like Centrecourr Asset Management and Smithline Family Trust and Retail investors are focused on Already established products offered by CV SCIENCES such as PlusCbd and PlusHLTH products. The Meat in the Meat and Potatoes 🥔 of the company. The dessert is being offered and delivered as the icing on the Cake.


Q: Do small companies in the CBD sector need to place a lot of money in sales and marketing, especially CV SCIENCES?

Ai Generated:

Yes, small CBD companies heavily rely on aggressive sales and marketing to survive, but strict industry regulations and tightening budgets—as seen with CV Sciences—are shifting the strategy from high-dollar mass advertising to more targeted, structural cost-efficiency.

The CBD marketing landscape dictates specific operational and financial approaches for small companies and legacy brands alike.

:Regulatory Hurdles: Direct paid advertising for CBD on platforms like Google and Meta is notoriously restricted, requiring small companies to spend creatively on SEO, content marketing, and influencer partnerships.

The CV Sciences.Pivot: CV Sciences (ticker: CVSI) previously invested heavily in sales and marketing to scale its PlusCBD brand. However, as the CBD market has tightened, the company has actively reduced its marketing spend to focus on cost-efficiencies, restructuring, and M&A.

Prioritizing ROI: Because of the tight regulatory climate, modern CBD marketing focuses heavily on education and trust-building. Many brands find higher returns on investment through email marketing and B2B expansion (e.g., placing products in retail, clinics, or dietary programs) rather than massive consumer ad spends.




Q: What are the stages of Introducing a new line of products such is the case for CV SCIENCES Lunar Fox line of products?

Ai Generated:

The corporate New Product Introduction (NPI) process requires a disciplined framework. This is explicitly true for wellness companies like CV Sciences, Inc., which expanded beyond its core hemp-derived CBD products to launch its Lunar Fox Food Co. plant-based food line.An organization navigates six key stages to move an innovation from a strategic idea to retail shelves:

1. Strategic Acquisition & Idea GenerationBefore a product is formulated, a firm establishes a strategic foundation. In the case of CV Sciences, this began with a major structural expansion—the acquisition of European manufacturer Cultured Foods.Core Action: Aligning the parent company's capital with new market infrastructure.Lunar Fox Focus: Transitioning established European plant-based manufacturing capabilities to serve the U.S. market.

2. Business Case Development & Regulatory ScrutinyFirms evaluate the financial viability and legal hurdles of entering an entirely new sector.Core Action: Conducting competitor analysis and evaluating the Addressable Market.Lunar Fox Focus: Assessing the fast-growing U.S. demand for vegan, gluten-free, and 100% natural foods. CV Sciences had to ensure these items met non-CBD food compliance separate from their hemp operations.

3. Formulation & Concept ValidationFormulations must be rigorously tested to meet consumer expectations for quality and flavor.Core Action: Refining prototypes, choosing premium ingredients, and conducting quality control.Lunar Fox Focus: Creating 100% natural, vegetarian-friendly alternatives to popular foods while matching CV Sciences' rigorous scientific and manufacturing standards.

.4. Brand Positioning & Go-To-Market Strategy A dedicated brand identity is built to differentiate the line from existing parent offerings.Core Action: Finalizing brand messaging, packaging design, and pricing structures.Lunar Fox Focus: Designing the "Lunar Fox Food Co." sub-brand to appeal broadly to clean-eating consumers, moving intentionally away from the medicinal "PlusCBD" aesthetic.

5. Product Launch & CommercializationThe commercial pipeline goes live, flooding targeted sales channels with marketing to drive consumer awareness.Core Action: Executing public relations blitzes, digital media launches, and dispatching sales forces.Lunar Fox Focus: Announcing a sweeping introduction of dozens of new plant-based products to U.S. distribution channels.

6. Post-Launch Review & Supply Chain Optimization Once the product is in the "Introduction" phase of its life cycle, management monitors sell-through data and supply chains.Core Action: Tracking margins, identifying top-performing SKUs, and realizing operational synergies.Lunar Fox Focus: Evaluating immediate consumer responses to the plant-based line to optimize inventory management alongside their core wellness supplements.

Ask Amazon? More like ask why they don't sell Lunar on Amazon. Did something happen when they tried selling Acute/Defense with them?

WQLF SAYS : B2B and B2C is doing just fine and Cost savings in sales and marketing is as well. The year is 2026. This is not how sales and marketing was done in the past thanks to the Internet and technology. Ask Amazon how they are doing with their sales and marketing programming. It is a GR8 opportunity to buy CVSI at discount rates. Ask Centrecourt Asset Management and Smithline Family Trust Buyer's and the retail investors
YQU Now Understand YQU Understand. Have Mercy WQLF ahoooooo

. The Naysayer Troll 🧌 Said :

And how about an update on Cultured Foods under Lunar Fox label with zero sales/marketing investment doing?

Q: Is it true that CV SCIENCES Combines their Cultured Foods and Lunar Fox revenue with their CBD Revenue?

Ai Generated:

Yes, this is true. Like many diversified consumer packaged goods companies, CV SCIENCES reports all of its sales—including those from CBD products, Cultured Foods, and Lunar Fox—under one consolidated revenue stream in its financial reporting.Here is how the company structures its finances:Consolidated Product Sales: In its SEC filings (such as its Form 10-K),

CV SCIENCES reports its total sales net under a single Product Sales line item. All revenue from Cultured Foods and Lunar Fox is grouped together with their core CBD brands (like +PlusCBD).Diversification Strategy: As the broader CBD market has faced regulatory hurdles and saturation,

CV SCIENCES acquired Cultured Foods in late 2023 and launched Lunar Fox in 2025 to transition into a broader health and wellness company. They use these non-cannabinoid brands to bolster and diversify their overall revenue.

Operational Breakdown: While they combine the top-line revenue numbers, the company does break down qualitative business highlights, such as the volume of B2B/B2C sales and operational synergies, within their press releases and shareholder reports.

Looks like a ceiling of $0.025 may be the new $0.03 on this stock. Who think they’re one more “going concern” acquisition away from taking it under $0.02?

And how about an update on Cultured Foods under Lunar Fox label with zero sales/marketing investment doing?

WQLF SAYS: It Appears that Centrecourt Asset Management and Smithline Family Trust are Angel 😇 Investors in Disguise YQU Now Understand YQU Understand...Have Mercy WQLF ahoooooo

Q: Is there a connection between Streeterville Capital and Maxim Group?

Ai Generated:

Yes, Streeterville Capital and Maxim Group frequently collaborate in the financial markets, operating together as strategic partners on corporate financing deals.While they are entirely separate entities, their professional relationship centers around raising capital for small-cap and emerging-growth companies.The connection typically functions as follows:

Financing Providers: Streeterville Capital often provides capital to public companies through convertible notes or securities purchase agreements.

Placement Agents: Maxim Group LLC acts as the investment banker and exclusive placement agent for these transactions. In this role, Maxim Group secures the financing deal and earns a cash fee or commission based on the gross proceeds of the transaction.

Selling Security holders: Because of their joint involvement, both entities are frequently listed as selling security holders in prospectuses when companies register their common shares for resale.



Q: What is Maxim Group's connection to Centrecourt Asset Management and Smithline Family Trust?

Ai Generated:

Maxim Group, Centrecourt Asset Management, and the Smithline Family Trust frequently act as interlocking partners in small-cap and micro-cap corporate financing.Key Figure: Richard (William) Smithline is the founder and Chairman of Centrecourt Asset Management.The Smithline Connection: The Smithline Family Trust (along with Centrecourt) frequently operates as an institutional investor or participating purchaser in structured investments, convertible notes, and private placements for emerging growth and micro-cap companies.

Maxim Group's Role: Maxim Group, a New York-based investment bank, often serves as the Placement Agent or Underwriter for these exact financing deals, connecting publicly traded issuers with investors like Centrecourt and the Smithline Family Trust.



Q: What is CV SCIENCES Connection with the Maxim Group?

Ai Generated :

The connection between CV Sciences, Inc. and the Maxim Group LLC is a strategic corporate partnership where Maxim Group serves as the company's non-exclusive financial advisor and investment banker.CV Sciences appointed Maxim Group to this role to accelerate both its organic and non-organic growth initiatives.

Key Aspects of the Partnership M&A and Strategic Options: The Maxim Group helps CV Sciences evaluate potential inbound and outbound mergers, sales, and acquisitions. This supports CV Sciences’ goal to actively participate in the ongoing consolidation of the health, wellness, and hemp industries.

Platform Expansion: With Maxim Group’s guidance, CV Sciences focuses on scaling an efficient, cost-effective consumer products platform. This follows their acquisition strategies, such as purchasing Elevated Softgels and Cultured Foods.

Capital & Financing Guidance: As an investment banking partner, Maxim Group provides specialized advisory services tailored to micro-cap and emerging growth companies navigating the capital markets.

WQLF SAYS:: What is Life without Smithline Family Trust You Now Understand YQU Understand. Have Mercy WQLF ahoooooo

Dr. Joong J Fang Said: Did you know that Wolfie coached and managed NFL Hall of Famer Bruce Smith (Number 78 )as a nine year old little League baseball player starting on April 7,1973 and was visited by Wolf a/k/a Robert Smith as he was programming the Wolfman Jack Syndicated Show on August 23,1974. And later on July 8th 1995 ( 7/8 ) while helping out with the Ceremony, Wolfie placed dirt in Wolf's grave at Wolf's Celebration of Life Ceremony.. Wolfie has a Lifeline of connections with Smith's. Destiny and Synchronicity at its finest.




Q: Why would Centrecourt Asset Management want to take a large position in CV SCIENCES Stock ?

Ai Generated:

Centrecourt Asset Management, an investment firm specializing in small-capitalization and lower middle-market companies, would likely target a large position in CV Sciences, Inc. (CVSI) to capitalize on deep-value, high-risk turnaround scenarios within the consumer wellness and healthcare sectors.Specific drivers for taking a major position include.

Extreme Valuation Upside: Trading as a penny stock (around $0.03) with a tiny market capitalization, a fractional shift in share price—often tied to a breakthrough in federal hemp regulations or new product lines like Ignite—translates to massive percentage returns for an institutional investor.

Institutional Restructuring & Financing: Centrecourt specializes in restructuring expertise. Because of their background in creative financing, they may view the equity stake as a strategic foothold to provide debt financing, help secure mergers, or structure capital to stabilize the company's balance sheet.

Emerging Market Catalysts: The wellness industry is volatile but has bright spots, such as emerging clinical applications for CBD and participation in highly regulated Medicare pilot programs. Taking a large position allows an active partner to steer operations and push toward profitability in a consolidating market.

Wolfman Jack Said: Have Mercy ahoooo:

https://share.google/pZkkzSPBRwgc88aWJ

The Celebration of Life Ceremony for legendary radio DJ Wolfman Jack (born Robert Weston Smith) took place on Saturday, July 8, 1995.The service was a joyful, fitting tribute held at his home in Belvidere, North Carolina, on the banks of the Perquimans River. Hundreds of fans, bikers, and radio industry colleagues gathered for the ceremony, which featured gospel music and a celebration of his life rather than a traditional, somber funeral.He passed away just a week prior on July 1, 1995, at the age of 57.

WQLF SAYS: Oh My My YQU Now Understand YQU Understand. Have Mercy WQLF ahoooooo

Q: How was Smithline Family Trust able to acquire CV SCIENCES IP and Trademarks?

Ai Generated:

The Smithline Family Trust (specifically Smithline Family Trust II) acquired the intellectual property and trademarks of CV Sciences not through an outright purchase, but as a collateral seizure to settle unpaid debt or to secure a loan.

The trust was able to take control of these assets through the following mechanisms:Secured Collateralization: William Smithline (acting as assignee or representing related entities such as Puritan Partners LLC) provided structured financing or debt to CV Sciences. As a condition of this financing, CV Sciences pledged its core IP—including its patents and trademarks—as collateral.Assignment and Security Agreements: Public records from the United States Patent and Trademark Office (USPTO) show that CV Sciences' pharmaceutical formulations and various trademarks were formally assigned to the Smithline Family Trust II as a recorded security interest.

Loan Default or Restructuring: When CV Sciences faced financial strain or defaulted on the debt agreements, the security agreements allowed the Smithline Family Trust to legally claim the pledged intellectual property to satisfy the outstanding obligations.



Q: When did Smithline Family Trust acquire CV SCIENCES IP and Trademarks?

Ai Generated:

The Smithline Family Trust did not acquire the intellectual property (IP) and trademarks of CV Sciences outright. Instead, the trust—via Centrecourt Asset Management—was listed as an assigned owner for specific CV Sciences patents and IP as collateral for structured financing and debt agreements.



Q: What is the date of the acquisition of CV SCIENCES IP and Trademarks by Smithline Family Trust occur?

Ai Generated :

There is no public record of an acquisition of CV Sciences' Intellectual Property (IP) and Trademarks by the Smithline Family Trust.Instead, Smithline Family Trust II was assigned a security interest/collateral assignment on CV Sciences' patents and IP (such as for their smokeless tobacco addiction treatment) on April 7, 2020. This arrangement stems from prior financing, licensing, or settlement transactions.Would you like to explore more about CV Sciences' recent patent restructuring, or look into the specific details of the financial agreements they've had with Smithline Family Trust? Let me know how to proceed!

Wolfman Jack Said: ahoooooo

https://share.google/9JSw0KRhTc4UahxLr

💥🍿 Breaking News:

💥🍿 Damn😳. DJT posted this on his Truth account and I DID NOT SEE THIS COMING🫨! Hemp is a miracle plant that our Government should embrace and study👊. Maybe have Chapel Hill study it instead of creating our next bull 💩 virus😲! Yeh, I went there🇺🇸

FOLLOW ME, THE NEXT DROP WILL… pic.twitter.com/j6R6m3eSjb— John Fitzgerald Kennedy Jr. (@MrJohnJnr) June 12, 2026

💥 https://pubmed.ncbi.nlm.nih.gov/41418992/

💥 https://pubmed.ncbi.nlm.nih.gov/42269696/

WQLF SAYS: After the Streeterville Capital Conversion of shares and diverted to Centrecourt Asset Management and Smithline Family Trust, they will have accumulated around 75 Million Shares or 30 percent of the Outstanding Shares. Will they both own 15 percent each? Have Mercy WQLF ahoooooo

Q: How long does Centrecourt Asset Management hold stock similar to CV SCIENCES ?

Ai Generated:

Centrecourt Asset Management operates as a private equity and asset management firm, meaning it generally holds investments in small-capitalization companies for 3 to 7 years rather than engaging in rapid, short-term day trading.

Because they often invest across the capital structure (structuring a mix of debt and equity) to take an active partnership role, their hold periods depend heavily on the specific growth, exit, or restructuring timeline of the portfolio company.Reviewing how this relates to a stock like CV Sciences (a smaller-cap life sciences/consumer wellness company) requires looking at typical investment parameters:

Typical Investment Targets: Centrecourt targets lower-middle-market and small-cap businesses, typically those under $300 million in market capitalization.Investment.

Style: Rather than treating stocks as liquid, short-term trades, Centrecourt executes buyouts, recapitalizations, and growth capital funding, working closely with management to drive value until a liquidity or exit event occurs.

.Asset Type: While they can hold common equity, they heavily favor combining these with debt securities and "equity features" that permit long-term upside.


Q: Could Centrecourt Asset Management be in a position to buy the converted cv Sciences stock from Streeterville Capital ?

Ai Generated:

Yes, Centrecourt Asset Management (CAM) and its associated entities or principals could be in a position to acquire or manage assets related to CV Sciences (CVSI).

Centrecourt and Streeterville Capital both specialize in alternative investments, debt restructuring, and small-cap financing.

Institutional investors or asset managers frequently acquire, swap, or take assignments of convertible notes, warrants, and converted common stock from one another to consolidate debt positions or execute secondary market block trades.

Additionally, financial discussions within the shareholder base suggest that Centrecourt-affiliated individuals or entities have previously been involved with CV Sciences' intellectual property, trademarks, or financing structures, aligning with CAM’s business model of taking on distressed debt and corporate restructuring.




Q: How is Centrecourt Asset Management linked to CV SCIENCES IP and trademarks?

Ai Generated:

Centrecourt Asset Management is linked to CV Sciences through the Smithline family and associated trusts, which hold and manage the intellectual property (IP) and trademarks of CV Sciences. William Smithline is the designated owner and controlling party associated with these assets, often through trust entities like the Smithline Family Trust.These IP assets, including trademarks for the company's core hemp-derived and nutraceutical products (such as PlusCBD), are often utilized in convertible note and financing agreements typical of over-the-counter (OTC) corporate funding.

💥🍿 CV Sciences https://www.cannabisbusinesstimes.com/industry-headlines/news/15827096/cbd-isolate-market-size-to-reach-usd-920-billion-by-2033-growing-at-142-cagr-driven-by-regulatory-clarity-formulation-innovation-and-standardized-manufacturing?utm_source=&utm_medium=email&utm_campaign=2728&pu_ext_id=67070220c792572c08f3ab2c

💥🍿CVSI-007… https://themarijuanaherald.com/2026/06/study-finds-inhaled-cbd-reversed-seizure-and-inflammation-related-effects-of-chronic-nicotine-exposure/
💥 https://themarijuanaherald.com/2026/06/study-finds-medical-cannabis-linked-to-long-term-improvements-in-hypermobility-related-chronic-pain/

💥 https://themarijuanaherald.com/2026/06/study-highlights-endocannabinoid-systems-role-in-muscle-health-and-cbds-therapeutic-potential/

💥 https://pubmed.ncbi.nlm.nih.gov/42262473/

💥🤗 https://themarijuanaherald.com/2026/06/nearly-200-cannabis-studies-published-in-2026/

💥 Today’s Breaking News:

💥🍿 https://www.congress.gov/bill/119th-congress/house-bill/7987/cosponsors

💥🍿 https://www.congress.gov/bill/119th-congress/house-bill/5068/cosponsors

💥 https://themarijuanaherald.com/2026/06/cbd-shows-potential-for-improving-sleep-and-reducing-seizures-in-angelman-syndrome-2/

💥 https://themarijuanaherald.com/2026/06/cannabinoid-treatments-show-promise-for-phantom-limb-pain-in-university-of-miami-study/

💥 https://www.marijuanamoment.net/marijuana-extracts-meaningfully-improve-cancer-patients-symptoms-such-as-sleep-trouble-and-anxiety-study-shows/
💥 https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.12070

💥 https://pubmed.ncbi.nlm.nih.gov/42262723/

WQLF SAYS: CV SCIENCES Plus CBD Products are Eligible according to the CMS Guidelines. Have Mercy WQLF ahoooooo

. TANK SAID: However, seniors cannot simply buy them and get Medicare reimbursement. A participating CMS model provider would have to choose eligible products, include them in a clinician-directed care plan, and furnish them under the pilot.


Q: Does CV SCIENCES CBD Line of Products qualify for the CMS Medicare Pilot Program ?

Yes, CV Sciences' products qualify. Under the CMS Substance Access Beneficiary Engagement Incentive (BEI), participating doctors can provide up to $500 per year in eligible CBD products to qualifying Medicare beneficiaries at zero cost.

CV Sciences’ broad line of hemp-derived cannabidiol products (often marketed under the PlusCBD brand) meets the strict quality benchmarks required by CMS.

CMS Pilot Program Product Requirements to be eligible for the CMS pilot, products must satisfy the following criteria:Source: Must be legally compliant, hemp-derived, and contain no more than 0.3% delta-9 THC.Dosage: Oral products must contain no more than 3 mg per serving of tetrahydrocannabinols.

Prohibited Items: Inhalable products (like vapes) are expressly excluded.

How the Pilot Program Works not an over-the-counter benefit: You cannot simply buy a CV Sciences product at a store and submit a bill to Medicare. The products must be provided directly through an eligible healthcare provider.

Participation restrictions: Access is currently limited to specific programs like ACO REACH and the Enhancing Oncology Model (EOM).

Physician oversight: Your care provider must determine that CBD use is appropriate for your symptoms and health situation.





"There are strict regulations on qualifying products. CBD products must be hemp-derived, sourced from legally compliant farms, and tested for cannabinoid content, contaminants, and safety. A product may not contain more than 0.3% delta-9 THC by dry weight and no more than three milligrams of total THC per serving. Inhalable products and synthetic or non-naturally occurring cannabinoids are excluded. Also, products must comply with federal, state, and local laws."

"Of concern is that CBD products must comply with federal, state, and local laws. This means seniors in some states will not get access to the most desirable CBD products to meet their needs, as the laws are very restrictive. "


https://cbd.market/news/medicare-program-covers-cbd-products

💥🍿 https://www.google.com/search?smstk=ChhlWkNtWVBFa0x6VFFDL1hDekkzdVcxcz0QAQ%3D%3D&smstidx=0&q=whtats+the+current+relationship+between+cv+sciences+and+maxim+group+%3F&udm=50&csuir=1&aep=34&kgs=ec2912c71f7fdcd1&shem=rimspwouoe&shndl=37&shmd=H4sIAAAAAAAA_3WOPWoDMRBG41TGTSBlqiGlIau4cREMqXIOMSsN0sDqh9FstKWLHCpn8Km8hqQKaT9473u7r_vdR4-K2kAjgZtFKCsITahccotcYSTtRBncJzTHlB01wOwh4cIJgpS5wvvTKarW9mZM730IbVWyG1xJphGKiy9VSioGOdkWUchqnNOYkaeh5vD8-EuHUsJEA7LZ3y3nh_Pme3vZ2P_cnDBQM6OsPZzDDx1sEPRrqZrD8mezK589ireH46uvt_srOCvEFwcBAAA&shmds=v1_ATWGeePDxO9E8CTr3-rXo5-HjXCQpVUllyj5D_rbrmvP4XpmzA&source=sh%2Fx%2Faim%2Fm1%2F1&mtid=SJgpapaFA6akiLMP1afjuAU. 🤗

💥 More Breaking CBD News:

💥 https://themarijuanaherald.com/2026/06/cbd-shows-potential-for-improving-sleep-and-reducing-seizures-in-angelman-syndrome-2/

💥 https://themarijuanaherald.com/2026/06/cannabinoid-treatments-show-promise-for-phantom-limb-pain-in-university-of-miami-study/

💥 https://www.marijuanamoment.net/marijuana-extracts-meaningfully-improve-cancer-patients-symptoms-such-as-sleep-trouble-and-anxiety-study-shows/

💥 https://themarijuanaherald.com/2026/06/cbd-rich-oil-shows-neuroprotective-effects-in-parkinsons-disease-study-finds/

💥 https://www.academia.edu/3071-4087/2/2/10.20935/AcadNeurosci8343

CV Sciences offers several PlusCBD oral hemp products that could potentially fit CMS Substance Access BEI requirements, including THC-free CBD gummies, THC-free softgels, full-spectrum CBD oils, and low-THC Reserve gummies/softgels. However, seniors cannot simply buy them and get Medicare reimbursement. A participating CMS model provider would have to choose eligible products, include them in a clinician-directed care plan, and furnish them under the pilot.